Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy

Medicine and Dentistry

• Immunotherapy 100%
• Non Small Cell Lung Cancer 100%
• Neoplasm 50%
• Treatment Response 50%
• Solid Malignant Neoplasm 50%
• Antineoplastic Activity 50%
• Salvage Therapy 50%
• Nivolumab 50%
• Steroid Therapy 50%
• Pembrolizumab 50%
• Immune-Related Adverse Events 50%
• Infliximab 50%
• Immune Checkpoint Inhibitor 50%
• Immune System 50%

Keyphrases

• Pneumonitis 100%
• Anti-programmed Death 1 100%
• Non-small Cell Lung Cancer (NSCLC) 40%
• Severe Cases 40%
• Immune System 20%
• Antitumor Activity 20%
• Tumor Response 20%
• Solid Tumors 20%
• Therapeutic Response 20%
• Mild Cases 20%
• Nivolumab 20%
• Variable Presentations 20%
• Immune-related Adverse Events 20%
• Pembrolizumab 20%
• Anti-programmed death-1 Therapy 20%
• Steroid-refractory 20%
• Programmed death-1 Inhibitor 20%
• Infliximab 20%
• Immune Checkpoint Inhibitors 20%
• Steroid Therapy 20%
• Salvage Therapy 20%

Immunology and Microbiology

• Immunotherapy 100%
• Pneumonitis 100%
• Antineoplastic Activity 20%
• Nivolumab 20%
• Infliximab 20%
• Pembrolizumab 20%
• Immune System 20%